Investors in Skye Bioscience Face Class Action for Claims of Misrepresentation

A Call for Skye Bioscience Investors

Bronstein, Gewirtz & Grossman, LLC, a leading law firm specializing in securities fraud cases, has announced a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE). This lawsuit arises from substantial losses incurred by investors during the specified class period, from November 4, 2024, to October 3, 2025.

Background of the Case

The firm warns that any individual or entity that purchased or acquired Skye's securities within this timeframe may have grounds to join the ongoing litigation. The allegations claim that Skye’s executives made misleading statements regarding the operational effectiveness and market prospects of its flagship product, nimacimab. Investors contend that these statements led to inflated stock valuations that do not reflect the true nature of the product’s performance.

Key Allegations:

1. Misleading Statements: The complaint asserts that company officials misrepresented the effectiveness of nimacimab, suggesting that it was yielding results that were not substantiated by clinical data.
2. Overstatements of Prospects: Investors argue that Skye's public disclosures exaggerated the regulatory and commercial potential of nimacimab, affecting stock price significantly.
3. Impacts on Shareholders: Due to these alleged misrepresentations, shareholders saw a distortion of the actual value, which contributed to their losses when the truth about the product's viability surfaced.

Legal Developments

As of now, the class action has been formally filed and is ongoing. Individuals interested in reviewing the full complaint or joining the lawsuit can visit the dedicated page on Bronstein’s website.

Next Steps for Investors

Affected investors are urged to act promptly, as the deadline to request being appointed as lead plaintiff is January 16, 2026. However, participation in the class doesn't require serving as lead plaintiff; affected parties can still pursue potential recovery without this role.

Financial Considerations

Importantly, this lawsuit is being pursued on a contingency fee basis, meaning there’s no upfront cost to join. The legal team operates under the principle that they will only recoup costs and fees if there is a successful recovery from the lawsuit.

Why Choose Bronstein, Gewirtz & Grossman?

With a robust history of representing investors in securities fraud lawsuits, Bronstein, Gewirtz & Grossman has successfully recovered hundreds of millions on behalf of clients nationwide. Their experienced team is dedicated to ensuring that investors’ rights are preserved and that they receive fair representation in the legal system.

For ongoing updates, investors can follow the law firm on social platforms such as LinkedIn, X (formerly Twitter), Facebook, and Instagram.

If you believe you have been adversely affected by your investment in Skye Bioscience, don't hesitate to reach out for more information. You can contact Peretz Bronstein or Nathan Miller directly at 332-239-2660 for assistance or to discuss your options.

The team at Bronstein is committed to guiding you through this process and ensuring you have the best chance at recovering your losses. As always, keep in mind that speculative investments in public companies carry risks, and it's crucial to stay informed about the viability of your assets.